Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 26;13(6):134.
doi: 10.3390/ph13060134.

Probing the Kinetic and Thermodynamic Fingerprints of Anti-EGF Nanobodies by Surface Plasmon Resonance

Affiliations

Probing the Kinetic and Thermodynamic Fingerprints of Anti-EGF Nanobodies by Surface Plasmon Resonance

Salvador Guardiola et al. Pharmaceuticals (Basel). .

Abstract

Despite the widespread use of antibodies in clinical applications, the precise molecular mechanisms underlying antibody-antigen (Ab-Ag) interactions are often poorly understood. In this study, we exploit the technical features of a typical surface plasmon resonance (SPR) biosensor to dissect the kinetic and thermodynamic components that govern the binding of single-domain Ab or nanobodies to their target antigen, epidermal growth factor (EGF), a key oncogenic protein that is involved in tumour progression. By carefully tuning the experimental conditions and transforming the kinetic data into equilibrium constants, we reveal the complete picture of binding thermodynamics, including the energetics of the complex-formation transition state. This approach, performed using an experimentally simple and high-throughput setup, is expected to facilitate mechanistic studies of Ab-based therapies and, importantly, promote the rational development of new biological drugs with suitable properties.

Keywords: EGF; SPR; antibody–antigen (Ag–Ab) interactions; biophysics; molecular recognition; nanobodies; thermodynamics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Binding kinetics of Nb1 (A) and Nb6 (B) to EGF at 25 °C. Nanobodies were injected at increasing concentrations over immobilised EGF, and the association and dissociation phases of all injections were fitted to a 1:1 Langmuir binding model. Two different surface densities were used for kon, koff and KD determination, with the corresponding background responses subtracted. Double-referenced sensorgrams for the highest density channel are shown here. Experiments were performed in duplicates. Residual errors from the fits are shown in the bottom panels.
Figure 2
Figure 2
Temperature dependence of binding kinetics and thermodynamic characterisation. Nb1 (A) and Nb6 (B) were injected over immobilised EGF at the indicated temperatures. For clarity, only sensorgrams of a single analyte concentration (70 nM) are shown. (C) Van’t Hoff plots representing the variation of the equilibrium association constants (KA) with the inverse of temperature. Data points were fitted to a second-order polynomial equation from which ΔG, ΔH, ΔS and ΔCp values were determined, following Equation (3). (D) Enthalpy (ΔH) and entropy (−TΔS) contributions to the free energy of binding (ΔG) for each Nb at 25 °C.
Figure 3
Figure 3
Transition state thermodynamics analysis. (A,B) Eyring plots representing the variation of the association constant (kon) with the inverse of temperature for Nb1 and Nb6. Linear fitting of the experimental data points to Equation (4) (ΔCp = 0) was performed in (A), while non-linear fitting was performed in (B). (C) Eyring plots for the dissociationn step of Nb1 and Nb6. Data were fitted to a second-order polynomial from which the transition state thermodynamic parameters were derived according to Equation (4). (D) Binding profile of Nb1 and Nb6 illustrating the transitions in ΔG, ΔH, ΔS at 25 °C. [EGF–Nb] represents the transition state.

References

    1. Flajnik M.F., Kasahara M. Origin and evolution of the adaptive immune system: Genetic events and selective pressures. Nat. Rev. Genet. 2010;11:47–59. doi: 10.1038/nrg2703. - DOI - PMC - PubMed
    1. Schroeder H.W. The evolution and development of the antibody repertoire. Front. Immunol. 2015;6:33. doi: 10.3389/fimmu.2015.00033. - DOI - PMC - PubMed
    1. Freise A.C., Wu A.M. In vivo imaging with antibodies and engineered fragments. Mol. Immunol. 2015;67:142–152. doi: 10.1016/j.molimm.2015.04.001. - DOI - PMC - PubMed
    1. Zolot R.S., Basu S., Million R.P. Antibody-drug conjugates. Nat. Rev. Drug Discov. 2013;12:259–260. doi: 10.1038/nrd3980. - DOI - PubMed
    1. Borrebaeck C.A.K. Antibodies in diagnostics—From immunoassays to protein chips. Immunol. Today. 2000;21:379–382. doi: 10.1016/S0167-5699(00)01683-2. - DOI - PubMed